These data suggest that zurletrectinib may be more effective than other next-generation TRK inhibitors in the clinic, especially in patients with brain metastasis [36] or NTRK fusion-positive gliomas that harbor TRK xDFG mutations. The gene discussed is TPM3; the disease is metastasis.